Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix long-term safety extension in prostate cancer
NCT00215683Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Feb 2005
- Primary completion
- Oct 2009
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label trial of degarelix in prostate cancer (PCa) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Participants With Markedly Abnormal Change in Vital Signs and Body Weight at 5 years and Liver Function Tests at 5 years. Started Feb 2005; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00215683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215683.